223 related articles for article (PubMed ID: 30707388)
1. DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes.
Davanso MR; Caliari-Oliveira C; Couri CEB; Covas DT; de Oliveira Leal AM; Voltarelli JC; Malmegrim KCR; Yaochite JNU
Inflammation; 2019 Apr; 42(2):449-462. PubMed ID: 30707388
[TBL] [Abstract][Full Text] [Related]
2. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Tian L; Gao J; Hao J; Zhang Y; Yi H; O'Brien TD; Sorenson R; Luo J; Guo Z
Endocrinology; 2010 Jul; 151(7):3049-60. PubMed ID: 20444936
[TBL] [Abstract][Full Text] [Related]
3. The effects of DPP-IV inhibition in NOD mice with overt diabetes.
Vargová L; Zacharovová K; Dovolilová E; Vojtová L; Cimburek Z; Saudek F
Folia Biol (Praha); 2013; 59(3):116-22. PubMed ID: 23890479
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
Karabulut S; Coskun ZM; Bolkent S
Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
[TBL] [Abstract][Full Text] [Related]
5. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats.
Eitah HE; Maklad YA; Abdelkader NF; Gamal El Din AA; Badawi MA; Kenawy SA
Toxicol Appl Pharmacol; 2019 Feb; 365():30-40. PubMed ID: 30576699
[TBL] [Abstract][Full Text] [Related]
6. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
[TBL] [Abstract][Full Text] [Related]
7. The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice
Li L; Lian X; Wang Z; Zheng J; Liu J; Chu Y; Teng Y; Zhang Z
Pharmazie; 2019 Apr; 74(4):239-242. PubMed ID: 30940309
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
9. A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
Li Z; Fang J; Jiao R; Wei X; Ma Y; Liu X; Cheng P; Li T
Biomed Pharmacother; 2017 May; 89():1467-1475. PubMed ID: 28376584
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
12. Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.
Alonso N; Julián MT; Carrascal J; Colobran R; Pujol-Autonell I; Rodriguez-Fernández S; Teniente A; Fernández MA; Miñarro A; Ruiz de Villa MC; Vives-Pi M; Puig-Domingo M
PLoS One; 2015; 10(11):e0142186. PubMed ID: 26555789
[TBL] [Abstract][Full Text] [Related]
13. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.
Pinheiro MM; Stoppa CL; Valduga CJ; Okuyama CE; Gorjão R; Pereira RM; Diniz SN
Eur J Pharm Sci; 2017 Mar; 100():17-24. PubMed ID: 28065853
[TBL] [Abstract][Full Text] [Related]
15. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
Hernández C; Bogdanov P; Solà-Adell C; Sampedro J; Valeri M; Genís X; Simó-Servat O; García-Ramírez M; Simó R
Diabetologia; 2017 Nov; 60(11):2285-2298. PubMed ID: 28779212
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M
J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922
[TBL] [Abstract][Full Text] [Related]
18. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S; Sole S
Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.
Ramírez E; Picatoste B; González-Bris A; Oteo M; Cruz F; Caro-Vadillo A; Egido J; Tuñón J; Morcillo MA; Lorenzo Ó
Cardiovasc Diabetol; 2018 Jan; 17(1):12. PubMed ID: 29325553
[TBL] [Abstract][Full Text] [Related]
20. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
